Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at or find her on LinkedIn.

Articles by Tracy Staton

CVS isn't stopping with PCSK9 discount demands. It wants concessions from ACC/AHA, too

CVS Health has no intention of shelling out more than it has to on the new PCSK9 drugs. It's been saying so for more than a year--and now, it has taken a double-barreled shot at the next-gen cholesterol fighters.

UPDATED: Medicare ponies up to pay extra for Amgen's $178K Blincyto

Medicare has changed its mind on Amgen's Blincyto--and for makers of other expensive cancer drugs, the news is good. The Centers for Medicare and Medicaid Services decided to shell out extra for the blood cancer drug, covering "add-on payments" made to hospitals for new treatments whose costs don't fit into standard lump-sum reimbursements.

Big Pharma feels the pain in China, with AZ delivering the only 10%-plus sales hike

Not so long ago, China was such a promising pharma market that drugmakers recruited hundreds of new sales reps to race after a share. But growth is slowing there now, and drug companies are feeling it.

Novo Nordisk beats in Q2 even as U.S. pricing pressures bite

Novo Nordisk keeps on putting up sales growth, with diabetes powerhouse Victoza leading the way. Its pipeline meds are moving along. But the question is whether that pipeline can start paying off soon enough to counteract increasing pricing pressure in the U.S.--and forthcoming biosimilars in Europe.

With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&A

Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics, not to mention a solid biosimilars pipeline.

Express Scripts stiff-arms AZ's Onglyza, Vivus' Qsymia with new 2016 formulary

Express Scripts has passed judgment for 2016. Some 20 new meds, including some closely watched products like Vivus' weight-loss med Qsymia, won't be covered on the pharmacy benefits manager's 2016 preferred formulary.

Bristol-Myers smashes Q2 as hep C meds rake in overseas sales

Here's an earnings trend-buster: Bristol-Myers Squibb trounced expectations for the second quarter and hiked its full-year sales forecast by more than $1 billion.

Roche clocks fast growth for new meds Perjeta, Esbriet as it girds for biosim rivalries

Roche isn't in denial about oncoming biosimilar competition for its top-selling cancer drugs. But CEO Severin Schwan says its new meds are on track to fill in the gap--and sales growth in the first half of the year go some way toward proving that case.

Should J&J break up? Get ready for a new round of debate

Johnson & Johnson has heard the advice before: Split up and reap the benefits. This time, it's CNBC's Jim Cramer making the call, and he figures the sum of J&J's parts would be 50% bigger than the whole is now. And he thinks an activist investor might step in and give J&J a push in that direction.

Bristol-Myers' next-gen HIV med gets FDA 'breakthrough' designation

Bristol-Myers Squibb nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use.